Payment overview · 2025
General Payments
$954.27
38 reported records · 10 companies
Healthcare provider profile · identity verified
Virgilio Celeste Ereso, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · CERES, CA · NPI 1720031685
Verified facts
What the public records show
CMS Open Payments records show Virgilio Celeste Ereso, M.D. received $954.27 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Ozempic, Rybelsus, Trelegy Ellipta, Xifaxan.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 148 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 298 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 249 claims for Rybelsus by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $375.77 | 39.4% | 10 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $216.24 | 22.7% | 11 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $97.48 | 10.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $76.22 | 8.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $45.73 | 4.8% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $42.92 | 4.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $32.30 | 3.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $27.40 | 2.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $23.31 | 2.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.90 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $954.27 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $315.02 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $263.11 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $260.58 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $144.06 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $97.48 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $76.22 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $56.12 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.55 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $45.73 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.92 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.30 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.63 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 148 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 298 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 95 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 249 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
148 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
298 | 64 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
298 | 64 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
95 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
249 | 49 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 885 | 97 |
| Atorvastatin Calcium | Atorvastatin Calcium | 586 | 155 |
| Lisinopril | Lisinopril | 517 | 134 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 117 |
| Hydrochlorothiazide | Hydrochlorothiazide | 403 | 99 |
| Gabapentin | Gabapentin | 318 | 54 |
| Oxycodone Hcl | Oxycodone Hcl | 317 | 31 |
| Metformin Hcl | Metformin Hcl | 314 | 83 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 300 | 81 |
| Jardiance | Empagliflozin | 298 | 64 |
| Alendronate Sodium | Alendronate Sodium | 280 | 71 |
| Alprazolam | Alprazolam | 269 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 48 |
| Rybelsus | Semaglutide | 249 | 49 |
| Omeprazole | Omeprazole | 245 | 53 |
| Levothyroxine Sodium | Levothyroxine Sodium | 243 | 54 |
| Losartan Potassium | Losartan Potassium | 234 | 66 |
| Carvedilol | Carvedilol | 183 | 50 |
| Clonazepam | Clonazepam | 169 | 19 |
| Potassium Chloride | Potassium Chloride | 158 | 35 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 31 |
| Farxiga | Dapagliflozin Propanediol | 148 | 36 |
| Linzess | Linaclotide | 138 | 30 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 137 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 35 |
| Ibuprofen | Ibuprofen | 127 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 122 | 21 |
| Furosemide | Furosemide | 121 | 26 |
| Eliquis | Apixaban | 120 | 22 |
| Benazepril Hcl | Benazepril Hcl | 106 | 22 |
| Baclofen | Baclofen | 104 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 99 | 13 |
| Temazepam | Temazepam | 97 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 96 | 11 |
| Ozempic | Semaglutide | 95 | 14 |
| Trazodone Hcl | Trazodone Hcl | 93 | 16 |
| Simvastatin | Simvastatin | 88 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 87 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 83 | 22 |
| Glimepiride | Glimepiride | 78 | 11 |
| Lorazepam | Lorazepam | 78 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 76 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 75 | 17 |
| Sertraline Hcl | Sertraline Hcl | 74 | 14 |
| Buspirone Hcl | Buspirone Hcl | 73 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 15 |
| Methadone Hcl | Methadone Hcl | 73 | suppressed |
| Famotidine | Famotidine | 70 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 20 |
| Diazepam | Diazepam | 69 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 68 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | suppressed |
| Ezetimibe | Ezetimibe | 61 | 13 |
| Xarelto | Rivaroxaban | 57 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 14 |
| Allopurinol | Allopurinol | 54 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | suppressed |
| Azithromycin | Azithromycin | 49 | 38 |
| Oxycontin | Oxycodone Hcl | 49 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 47 | suppressed |
| Naproxen | Naproxen | 47 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Finasteride | Finasteride | 44 | 11 |
| Montelukast Sodium | Montelukast Sodium | 44 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | suppressed |
| Telmisartan | Telmisartan | 41 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 40 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | 11 |
| Prednisone | Prednisone | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 31 | 24 |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Xtampza Er | Oxycodone Myristate | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Tradjenta | Linagliptin | 27 | 13 |
| Trulance | Plecanatide | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 22 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 16 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Sumatriptan Succ-Naproxen Sod | Sumatriptan Succ/Naproxen Sod | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 14 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Mesalamine | Mesalamine | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Kerendia | Finerenone | 13 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 13 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Etodolac | Etodolac | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Leflunomide | Leflunomide | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xifaxan | Rifaximin | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $954.27 · 38 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, EVENITY, FARXIGA, JARDIANCE, JASCAYD, Kerendia, LEQVIO, MOUNJARO, OFEV, Ozempic, PROLIA, Rybelsus, TRELEGY ELLIPTA, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error